SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Seagen Inc. (SGEN) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($171.82, 24.9%).
- Analyst consensus target $171.82 (-24.9% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SGEN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio21.53
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.30
Book Value / Share$0.00
Revenue / Share$10.63
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$171.82 (-24.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.51 |
$269.26M |
$-62.52M |
-23.2% |
| 2014 |
$-0.62 |
$286.76M |
$-76.14M |
-26.6% |
| 2015 |
$-0.93 |
$336.8M |
$-120.49M |
-35.8% |
| 2016 |
$-1.00 |
$418.15M |
$-140.11M |
-33.5% |
| 2017 |
$-0.88 |
$482.25M |
$-125.53M |
-26% |
| 2018 |
$-1.41 |
$654.7M |
$-222.69M |
-34% |
| 2019 |
$-0.38 |
$916.71M |
$-63.24M |
-6.9% |
| 2020 |
$3.37 |
$2.18B |
$613.67M |
28.2% |
| 2021 |
$-3.70 |
$1.57B |
$-674.47M |
-42.8% |
| 2022 |
$-3.30 |
$1.96B |
$-610.31M |
-31.1% |
